Adagrasib Patent Expiration
Adagrasib is Used for treating locally advanced or metastatic non-small cell lung cancer in adult patients with a specific KRAS mutation who have already undergone prior systemic therapy. It was first introduced by Bristol Myers Squibb Co
Adagrasib Patents
Given below is the list of patents protecting Adagrasib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Krazati | US10689377 | KRas G12C inhibitors | May 17, 2037 | Bristol |
Adagrasib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List